AUB ScholarWorks

Splenectomy and thrombosis: The case of thalassemia intermedia

Show simple item record

dc.contributor.author Taher A.T.
dc.contributor.author Musallam K.M.
dc.contributor.author Karimi M.
dc.contributor.author El-Beshlawy A.
dc.contributor.author Belhoul K.
dc.contributor.author Daar S.
dc.contributor.author Saned M.
dc.contributor.author Cesaretti C.
dc.contributor.author Cappellini M.D.
dc.contributor.editor
dc.date Oct-2010
dc.date.accessioned 2017-10-05T15:39:32Z
dc.date.available 2017-10-05T15:39:32Z
dc.date.issued 2010
dc.identifier 10.1111/j.1538-7836.2010.03940.x
dc.identifier.isbn
dc.identifier.issn 15387933
dc.identifier.uri http://hdl.handle.net/10938/16938
dc.description.abstract Background: Hypercoagulability in splenectomized patients with thalassemia intermedia (TI) has been extensively evaluated. However, clinical and laboratory characteristics of patients who eventually develop overt thromboembolic events (TEE) are poorly studied. Patients-Methods: Three Groups of TI patients (n = 73 each) were retrospectively identified from a registry involving six centers across the Middle East and Italy: Group I, all splenectomized patients with a documented TEE; Group II, age- and sex-matched splenectomized patients without TEE; and Group III, age- and sex-matched nonsplenectomized patients without TEE. Retrieved data included demographics, laboratory parameters, clinical complications, and received treatments that may influence TEE development, and reflected the period prior to TEE occurrence in Group I. Results: The mean age of Group I patients at development of TEE was 33.1 ± 11.7 years, with a male to female ratio of 33:40. TEE were predominantly venous (95percent) while four patients (5percent) had documented stroke. Among studied parameters, Group I patients weremore likely to have a nucleated red blood cell (NRBC) count ≥ 300 × 106 L-1, a platelet count ≥ 500 × 109 L-1 and evidence of pulmonary hypertension (PHT), or be transfusion nai[dotless]̈ve. The median time to thrombosis following splenectomy was 8 years. Patients with an NRBC count ≥ 300 × 106 L-1, a platelet count ≥ 500 × 109 L-1, or who were transfusion naive also had a shorter time to thrombosis following splenectomy. Conclusion: Splenectomized TI patients who will develop TEE may be identified early on by high NRBC and platelet counts, evidence of PHT, and transfusion naivety. © 2010 International Society on Thrombosis and Haemostasis.
dc.format.extent
dc.format.extent Pages: (2152-2158)
dc.language English
dc.publisher MALDEN
dc.relation.ispartof Publication Name: Journal of Thrombosis and Haemostasis; Publication Year: 2010; Volume: 8; no. 10; Pages: (2152-2158);
dc.relation.ispartofseries
dc.relation.uri
dc.source Scopus
dc.subject.other
dc.title Splenectomy and thrombosis: The case of thalassemia intermedia
dc.type Article
dc.contributor.affiliation Taher, A.T., Department of Internal Medicine, Hematology-Oncology Division, American University of Beirut Medical Center, Beirut, Lebanon
dc.contributor.affiliation Musallam, K.M., Department of Internal Medicine, Hematology-Oncology Division, American University of Beirut Medical Center, Beirut, Lebanon
dc.contributor.affiliation Karimi, M., Department of Pediatrics, Thrombosis and Hemostasis Unit, Hematology Research Center, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran
dc.contributor.affiliation El-Beshlawy, A., Department of Pediatrics, Cairo University, Cairo, Egypt
dc.contributor.affiliation Belhoul, K., Genetic and Thalassemia Center, Al Wasl Hospital, Dubai, United Arab Emirates
dc.contributor.affiliation Daar, S., Sultan Qaboos University, Muscat, Oman
dc.contributor.affiliation Saned, M., Genetic and Thalassemia Center, Al Wasl Hospital, Dubai, United Arab Emirates
dc.contributor.affiliation Cesaretti, C., Centro Anemie Congenite, Ospedale Maggiore Policlinico, IRCCS, Universitá di Milano, Milano, Italy
dc.contributor.affiliation Cappellini, M.D., Centro Anemie Congenite, Ospedale Maggiore Policlinico, IRCCS, Universitá di Milano, Milano, Italy
dc.contributor.authorAddress Taher, A.T.; Department of Internal Medicine, Hematology and Oncology Division, American University of Beirut Medical Center, PO Box 11-0236, Riad El-Solh 1107, 2020, Beirut, Lebanon; email: ataher@aub.edu.lb
dc.contributor.authorCorporate University: American University of Beirut Medical Center; Faculty: Faculty of Medicine; Department: Internal Medicine; Division: Hematology-Oncology;
dc.contributor.authorDepartment Internal Medicine
dc.contributor.authorDivision Hematology-Oncology
dc.contributor.authorEmail ataher@aub.edu.lb
dc.contributor.authorFaculty Faculty of Medicine
dc.contributor.authorInitials Taher, AT
dc.contributor.authorInitials Musallam, KM
dc.contributor.authorInitials Karimi, M
dc.contributor.authorInitials El-Beshlawy, A
dc.contributor.authorInitials Belhoul, K
dc.contributor.authorInitials Daar, S
dc.contributor.authorInitials Saned, M
dc.contributor.authorInitials Cesaretti, C
dc.contributor.authorInitials Cappellini, MD
dc.contributor.authorOrcidID
dc.contributor.authorReprintAddress Taher, AT (reprint author), Amer Univ Beirut, Med Ctr, Div Hematol and Oncol, Dept Internal Med, POB 11-0236,Riad El Solh 1107 2020, Beirut, Lebanon.
dc.contributor.authorResearcherID
dc.contributor.authorUniversity American University of Beirut Medical Center
dc.description.cited Aessopos A, 2005, CHEST, V127, P1523, DOI 10.1378-chest.127.5.1523; Aessopos A, 2001, BLOOD, V97, P3411, DOI 10.1182-blood.V97.11.3411; Aessopos A, 2007, TRANSFUSION, V47, P792, DOI 10.1111-j.1537-2995.2007.01192.x; Atichartakarn V, 2002, BRIT J HAEMATOL, V118, P893, DOI 10.1046-j.1365-2141.2002.03711.x; Barst RJ, 2004, J AM COLL CARDIOL, V43, p40S, DOI 10.1016-j.jacc.2004.02.032; BORENSTAINBENYASHAR V, 1993, AM J HEMATOL, V44, P63; Borgna Pignatti C., 1998, Acta Haematologica (Basel), V99, P76, DOI 10.1159-000040814; Cadili A, 2008, AM J MED, V121, P371, DOI 10.1016-j.amjmed.2008.02.014; CAMASCHELLA C, 1995, HAEMATOLOGICA, V80, P58; Cappellini MD, 2005, ANN NY ACAD SCI, V1054, P317, DOI 10.1196-annals.1345.039; Cappellini MD, 2000, BRIT J HAEMATOL, V111, P467, DOI 10.1046-j.1365-2141.2000.02376.x; Chen SQ, 1996, AM J PHYSIOL-HEART C, V270, pH1951; COSSU P, 1981, EUR J PEDIATR, V137, P267, DOI 10.1007-BF00443255; Crary SE, 2009, BLOOD, V114, P2861, DOI 10.1182-blood-2009-04-210112; DELPRINCIPE D, 1993, BRIT J HAEMATOL, V84, P111; Derchi G, 2005, HAEMATOL-HEMATOL J, V90, P452; ELDOR A, 1991, BLOOD, V77, P1749; Gladwin MT, 2008, NEW ENGL J MED, V359, P2254, DOI 10.1056-NEJMra0804411; Habib A, 2008, HAEMATOL-HEMATOL J, V93, P941, DOI 10.3324-haematol.12460; Helley D, 1996, THROMB HAEMOSTASIS, V76, P322; HERSHKO C, 1978, BRIT J HAEMATOL, V40, P255, DOI 10.1111-j.1365-2141.1978.tb03662.x; Isma'eel H, 2008, AM J CARDIOL, V102, P363, DOI 10.1016-j.amjcard.2008.03.066; KLEBER FX, 1992, BRIT HEART J, V67, P289; Kuypers FA, 2004, CELL MOL BIOL, V50, P147; Nathan DM, 2009, DIABETES CARE, V32, P193, DOI 10.2337-dc08-9025; O'Donnell A, 2007, P NATL ACAD SCI USA, V104, P9440, DOI 10.1073-pnas.0703424104; Pippard M J, 1988, Birth Defects Orig Artic Ser, V23, P29; Pootrakul P, 2003, BRIT J HAEMATOL, V122, P305, DOI 10.1046-j.1365-2141.2003.04412.x; Ruf A, 1997, BRIT J HAEMATOL, V98, P51, DOI 10.1046-j.1365-2141.1997.1502965.x; Rund D, 2005, NEW ENGL J MED, V353, P1135, DOI 10.1056-NEJMra050436; SHINAR E, 1989, J CLIN INVEST, V83, P404, DOI 10.1172-JCI113898; SONAKUL D, 1980, Southeast Asian Journal of Tropical Medicine and Public Health, V11, P516; STURGEON P, 1955, BRIT J HAEMATOL, V1, P264, DOI 10.1111-j.1365-2141.1955.tb05509.x; Sumiyoshi A, 1992, Southeast Asian J Trop Med Public Health, V23 Suppl 2, P29; Taher A, 2006, THROMB HAEMOSTASIS, V96, P488, DOI 10.1160-TH06-05-0267; Taher A, 2006, BLOOD CELL MOL DIS, V37, P12, DOI 10.1016-j.bcmd.2006.04.005; Taher AT, 2008, BLOOD REV, V22, P283, DOI 10.1016-j.blre.2008.04.001; Taher AT, 2010, J THROMB HAEMOST, V8, P54, DOI 10.1111-j.1538-7836.2009.03651.x; Taher AT, 2010, BLOOD, V115, P1886, DOI 10.1182-blood-2009-09-243154; Tavazzi D, 2001, BRIT J HAEMATOL, V112, P48, DOI 10.1046-j.1365-2141.2001.02482.x; Voskaridou E, 2010, BRIT J HAEMATOL, V148, P332, DOI 10.1111-j.1365-2141.2009.07930.x; Weatherall DJ, 2001, THALASSAEMIA SYNDROM; WEATHERALL DJ, 2010, BLOOD, DOI DOI 10.1182-BL00D-2010-01-251348; WINICHAGOON P, 1981, Southeast Asian Journal of Tropical Medicine and Public Health, V12, P556
dc.description.citedCount 39
dc.description.citedTotWOSCount 44
dc.description.citedWOSCount 42
dc.format.extentCount 7
dc.identifier.articleNo
dc.identifier.coden JTHOA
dc.identifier.pubmedID 20546125
dc.identifier.scopusID 78649339507
dc.identifier.url
dc.publisher.address COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
dc.relation.ispartofConference
dc.relation.ispartofConferenceCode
dc.relation.ispartofConferenceDate
dc.relation.ispartofConferenceHosting
dc.relation.ispartofConferenceLoc
dc.relation.ispartofConferenceSponsor
dc.relation.ispartofConferenceTitle
dc.relation.ispartofFundingAgency
dc.relation.ispartOfISOAbbr J. Thromb. Haemost.
dc.relation.ispartOfIssue 10
dc.relation.ispartOfPart
dc.relation.ispartofPubTitle Journal of Thrombosis and Haemostasis
dc.relation.ispartofPubTitleAbbr J. Thromb. Haemost.
dc.relation.ispartOfSpecialIssue
dc.relation.ispartOfSuppl
dc.relation.ispartOfVolume 8
dc.source.ID WOS:000282642500009
dc.type.publication Journal
dc.subject.otherAuthKeyword Hypercoagulability
dc.subject.otherAuthKeyword Splenectomy
dc.subject.otherAuthKeyword Thalassemia intermedia
dc.subject.otherAuthKeyword Thromboembolism
dc.subject.otherChemCAS hydroxyurea, 127-07-1
dc.subject.otherChemCAS Codon
dc.subject.otherIndex anticoagulant agent
dc.subject.otherIndex antithrombocytic agent
dc.subject.otherIndex hydroxyurea
dc.subject.otherIndex adolescent
dc.subject.otherIndex adult
dc.subject.otherIndex aged
dc.subject.otherIndex article
dc.subject.otherIndex blood transfusion
dc.subject.otherIndex child
dc.subject.otherIndex controlled study
dc.subject.otherIndex deep vein thrombosis
dc.subject.otherIndex demography
dc.subject.otherIndex erythrocyte count
dc.subject.otherIndex female
dc.subject.otherIndex human
dc.subject.otherIndex Italy
dc.subject.otherIndex lung embolism
dc.subject.otherIndex major clinical study
dc.subject.otherIndex male
dc.subject.otherIndex Middle East
dc.subject.otherIndex portal vein thrombosis
dc.subject.otherIndex preschool child
dc.subject.otherIndex priority journal
dc.subject.otherIndex pulmonary hypertension
dc.subject.otherIndex retrospective study
dc.subject.otherIndex school child
dc.subject.otherIndex splenectomy
dc.subject.otherIndex superficial thrombophlebitis
dc.subject.otherIndex thalassemia
dc.subject.otherIndex thalassemia intermedia
dc.subject.otherIndex thrombocyte count
dc.subject.otherIndex thromboembolism
dc.subject.otherIndex Adolescent
dc.subject.otherIndex Adult
dc.subject.otherIndex Aged
dc.subject.otherIndex beta-Thalassemia
dc.subject.otherIndex Blood Coagulation
dc.subject.otherIndex Child
dc.subject.otherIndex Codon
dc.subject.otherIndex Female
dc.subject.otherIndex Humans
dc.subject.otherIndex Male
dc.subject.otherIndex Middle Aged
dc.subject.otherIndex Mutation
dc.subject.otherIndex Retrospective Studies
dc.subject.otherIndex Splenectomy
dc.subject.otherIndex Stroke
dc.subject.otherIndex Thromboembolism
dc.subject.otherIndex Thrombosis
dc.subject.otherKeywordPlus RED-BLOOD-CELLS
dc.subject.otherKeywordPlus VIVO PLATELET ACTIVATION
dc.subject.otherKeywordPlus BETA-THALASSEMIA
dc.subject.otherKeywordPlus HYPERCOAGULABLE STATE
dc.subject.otherKeywordPlus CHELATION-THERAPY
dc.subject.otherKeywordPlus IRON-OVERLOAD
dc.subject.otherKeywordPlus DISEASE
dc.subject.otherKeywordPlus PHOSPHATIDYLSERINE
dc.subject.otherKeywordPlus COMPLICATIONS
dc.subject.otherKeywordPlus ERYTHROCYTES
dc.subject.otherWOS Hematology
dc.subject.otherWOS Peripheral Vascular Disease


Files in this item

Files Size Format View

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record

Search AUB ScholarWorks


Browse

My Account